Group leader, Research Director (DR1), co-head of the CPTP
Centre de Physio-pathologie de Toulouse Purpan, France Inserm, France
The colonosphere culture is novel technique allowing to generate human intestinal epithelium in 3D while maintaining activity regionalization (proliferation, differentiation and apoptosis) of cellular types (immature and differentiated cells). Nuclei are represented in green, actin in cyan and the proliferation marker Ki67 in red.
Human colonosphere or “mini-gut” from in vitro from patient’s Lieberkühn’s crypts (picture credit Dr. E. d’Aldebert)
Nathalie Vergnolle identifies and characterizes mediators of inflammation and pain in intestinal pathologies (Irritable Bowel Syndrome (IBS), Infectious Colitis, Inflammatory Bowel Diseases (IBD), and Inflammation-Associated Colorectal Cancers).
The research focus of Nathalie Vergnolle’s INSERM team is focused on the study of four major intestinal pathologies: Irritable Bowel Syndrome (IBS), Infectious Colitis, Inflammatory Bowel Diseases (IBD), and Inflammation-Associated Colorectal Cancers.
Nathalie Vergnolle and her team aim at identifying and understanding the role and regulation of the mediators that are involved in inflammatory and pain mechanisms in the intestine during the course of those pathologies.
From this knowledge, they hope to identify new molecular targets that could be used for the treatment of those pathologies. Specifically, 4 major classes of molecules are studied: (1) the protease and their inhibitors, (2) the calcium channels of the transcient receptor potential (TRP) family, (3) the polyunsaturated fatty acid metabolites of the arachidonic cascade, and (4) the endogenous opioids of the enkephalin family.
Nathalie Vergnolle and her lab investigate the pathophysiology of the intestine as a whole, having developed both in vivo models of pathologies and in vitro models of cell cultures.
The specific objective of Nathalie Vergnolle’s lab is to improve our knowledge of the mechanisms responsible of inflammation and pain. Such knowledge of the mediators involved in chronic intestinal diseases would naturally highlight news pharmacological targets to cure these pathologies. Above all, the identified targets could also be considered for the treatment of chronic inflammatory diseases and pain in general.
Dernière mise à jour : 31 juillet 2014
• 1997 : PhD in Biology, University Toulouse III, France, Lionel Buéno’s laboratoy
• 1997-2000 : Postdoctoral fellow, University of Calgary, Canada, John Wallace’s laboratory
• 2000 : Appointed Assistant Professor, University of Calgary, Canada
• 2004 : Appointed Associate Professor, University of Calgary, Canada
• Distinguished Chevalier de la légion d'honneur, French State, 2013
• Woman In Inflammation Science Award, International Association of Inflammation Societies, 2013
• Starting Grant, European Research Council (ERC), 2012
• Laureate of the Avenir Program, Fondation Bettencourt-Schueller INSERM, 2006